, (Redox Bottleneck) , ,
GLP1 MODULATION OF THE HYPOTHALAMICPITUITARYOVARIAN AXIS ENHANCES FEMALE FERTILITY As described above, obesity is associated with diabetes and insulin resistance, sharing a common link with metabolic disorders like PCOS
[1] [2] It belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists , which work by mimicking the action of the naturally occurring hormone GLP-1
: 3
As a class of drugs, GLP-1s have been shown to result in weight loss.[2] Common side effects of GLP-1s include nausea, vomiting, diarrhea, constipation, injection site reactions, headache, hypoglycemia, dyspepsia, fatigue, dizziness, abdominal pain, and gastroenteritis.[1-4] All GLP-1s carry a boxed warning for the risk of thyroid c-cell tumors and a contraindication for a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
For oral peptides, bioavailability is typically very low, often in the single digits, because the gastrointestinal tract destroys most of the compound before it can be absorbed